AChE/BChE-IN-27

AChE/BChE-IN-27 (Compound 12d) (10 nM-100 μM 12 days) shows the high inhibitory effects with IC₅₀ values of 3.72 μM (AChE) and 9.65 μM (BChE)^[1].

AChE/BChE-IN-27 (1-30 μM, 37 °C, 30 min) exhibits mixed inhibitory effects on hAChE and eqBChE in enzyme kinetic assays^[1].

AChE/BChE-IN-27 (5-50 μM, 25 °C, 6 h) shows a PI displacement of 23.58 % in peripheral anionic site (PAS) inhibition studies against AChE^[1].

AChE/BChE-IN-27 (1.25-20 μM, 37 °C, 30 min) shows the most potent antioxidant activity in the DPPH (HY-112053) assay with an IC₅₀ value of 6.32 μM^[1].

AChE/BChE-IN-27 (500 μM, 37 °C, 18 h) exhibits a Pe value greater than 2.0, suggesting moderate BBB permeability (CNS ±)^[1].

AChE/BChE-IN-27 (18 μM, 5 min) could serve as a potential therapeutic agent for mitigating metal ion dysregulation^[1].

AChE/BChE-IN-27 (5 μM, 37 °C, 72 h) inhibits Aβ1-42 aggregation, results in the inhibition of Aβ1–42 fibril formation, demonstrating its potential as an aggregation modulator^[1].

AChE/BChE-IN-27 (5-80 μM, 24 h) shows no cytotoxicity in SH-SY5Y cells^[1].

AChE/BChE-IN-27 (5-80 μM, 24 h) can effectively protect SH-SY5Y cells from H₂O₂-induced neurotoxicity^[1].

AChE/BChE-IN-27 (1-80 μM, 24 h) reduces ROS levels and protects cells in SH-SY5Y cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.